Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Behind The Approval Letter: A Year Of Drug Review Profiles

This article was originally published in Pharmaceutical Approvals Monthly

You may also be interested in...



The Long Road To Approval: Acorda Experience With Ampyra Shows Success Of Novel Analysis Plan

Acorda Therapeutics' challenges in seeking approval for its oral therapy Ampyra to improve walking ability in patients with multiple sclerosis were greater than most from the start: it was a novel drug for a first-of-its-kind claim – and the drug yielded variable efficacy on an unproven endpoint. What seems to have made the difference is the creative analysis plan that Acorda came up with.

Ampyra Approval: Acorda's Lessons Learned

There are many factors that contributed to Acorda's success in gaining approval for Ampyra (dalfampridine), but looking back at the process, CEO Ron Cohen and Chief Scientific Officer Andy Blight agree that the biggest asset was having a Special Protocol Assessment for the Phase III trials.

HRA’s Efficient Ella Development Strategy Begat FDA’s Efficient NDA Review

The story of HRA Pharma’s emergency contraceptive Ella (ulipristal) bears many of the hallmarks of what many sponsors would consider a desirable regulatory path, culminating in a first-cycle approval with clean labeling.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS004631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel